Article Details

Ionis Opening Phase 3 Trial of ION363, Antisense Therapy for FUS-ALS

Retrieved on: 2021-04-07 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Ionis Opening Phase 3 Trial of ION363, Antisense Therapy for FUS-ALS. View article details on hiswai:

Excerpt

ION363 is a form of antisense therapy that targets messenger RNA (mRNA) — an intermediate molecule generated from DNA — with instructions for ...

Article found on: alsnewstoday.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up